Chronic Obstructive Pulmonary Disease: A Global Strategic Business Report
San Jose, California (PRWEB) February 15, 2010
Chronic Obstructive Pulmonary Disease (COPD) is a chronic, debilitating disease that affects millions of people worldwide. It is progressive in nature, and is characterized by chronic inflammation of the lung tissue. It often causes coughing, produces mucus, wheezing, chest tightness and shortness of breath. The two most common types of COPD are emphysema and chronic bronchitis. Despite the debilitating nature of the disease, the level of awareness about COPD is too poor among both developed as well as developing countries.
Though without a cure, COPD can be treated with early diagnosis and appropriate medication. The LABA/ICS (Long-acting beta2-agonists/Inhaled Corticosteroids) combination therapy class dominates the world COPD drugs market, as stated by the new market research report on chronic obstructive pulmonary disease. However, monotherapy with a beta2-agonist, or an anticholinergic, or a corticosteroid can also be used, depending on the stage and severity of the disease. Advair and Spiriva are the leading products for the treatment of COPD.
After remaining neglected for several years in the area of drug discovery and development, COPD of late has been prioritized as one of the major unmet medical needs by national governments, and pharmaceutical companies and healthcare workers the world over. While efforts are underway to raise awareness, several research programs dedicated to COPD discovery are ongoing. The pipeline comprises bronchodilators, including inhaled Long-acting beta2-agonists (LABAs) and Long-acting Muscarinic Antagonist (LAMA) candidates; anti-inflammatories, including inhaled corticosteroids and PDE IV inhibitors candidates; and combination products and other agents with novel mechanisms of action.
The global market for chronic obstructive pulmonary disease is highly consolidated. The market has traditionally remained a domain of large, multinational companies, primarily since research & development of inhaled drugs implies huge investment, significant regulatory hurdles, and a sales network that is substantially large and robust enough to market drugs to both primary care physicians and pulmonologists. This market, therefore, has been a home to pharma leaders such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer and Schering-Plough since several years. Nevertheless, small, niche companies such as Chiesi Pharmaceutici, Nycomed and Sepracor have of late successfully established presence in the market.
Key players profiled in the report include AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, Nycomed, Schering-Plough Corp., Sepracor Inc., and Vectura Group plc.
The report titled "Chronic Obstructive Pulmonary Disease: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the global market, competitive scenario, pipeline drugs, product approvals/introductions, and recent industry activity. The study analyzes market data and analytics in terms of value sales for the United States and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Chronic_Obstructive_Pulmonary_Disease_COPD_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc. (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/